Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Amy Raymond, PhD, PMP
Advertisement
Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials
Articles by Amy Raymond, PhD, PMP
Advertisement
Latest Updated Articles
Evolving Tools and Perspectives for the Development of Cell and Gene TherapiesPublished: May 16th 2023 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials
3
ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age
4
Building Broader Investigator Networks to Advance Global Breast Cancer Research
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
